axicabtagene ciloleucel
daiichi sankyo,gilead
['axi-cel', 'zuma-12', 'lymphoma']
presented at #ash21: in the phase 2 zuma-12 trial, first-line treatment with axi-cel #cartcells exhibited a high complete response rate and a manageable safety profile in adults with high-risk large b cell #lymphoma #ash22 
Nature Medicine is a research journal devoted to publishing the latest advances in translational and clinical research for scientists and physicians.